In a single-center study, Thiruvengadam S et al. discovered that the introduction of linagliptin at a median of 90 days post-transplant improved the calculated homeostatic model assessment of insulin resistance (HOMA-IR) score compared with the conventional treatment with insulin [100]. The gene discussed is INS; the disease is Insulin resistance.